Form 4 for KURA Kura Oncology, Inc.
Accepted 2025-12-19 00:00:00 ET · period of report 2025-12-18 · accession 0001193125-25-326948 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-19 | 2025-12-18 | KURA | Burrows Francis | CSO | S - Sale+OE | $9.78 | -23.7K | 33.7K | -41% | -$232.0K |
| D | 2025-12-19 | 2025-12-18 | KURA | Burrows Francis | CSO | M - OptEx | $4.80 | +35.0K | 57.5K | +156% | +$168.0K |
| D | 2025-12-19 | 2025-12-18 | KURA | Burrows Francis | CSO | M - OptEx | $0.00 | -35.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-18 | S | D | 23,726 | $9.78 | 33,735 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $9.77 to $9.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2025-12-18 | M | A | 35,000 | $4.80 | 57,461 | D | — | — | (F2) Includes 857 shares acquired on May 17, 2025 and 899 shares acquired on November 17, 2025 pursuant to the Issuer's Employee Stock Purchase Plan. |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-12-18 | M | D | 35,000 | $0.00 | 0 | D | $4.80 · — to 2026-01-29 | 35,000 Common stock | (F4) This option is fully vested. |